TABLE II.
Therapy type |
Patients
|
Involved lymph nodes (%) |
Median os (months)
|
||
---|---|---|---|---|---|
(n) | (%) | In whole group | In extrapancreatic disease | ||
Neoadjuvant | 39 | 8.5 | 45 | 34 | 31 |
Adjuvant | 419 | 91.5 | 65 | 19 | 19 |
p=0.011 | p=0.003 | p=0.018 | |||
| |||||
Neoadjuvant therapy as independent predictor of improved survival: hazard ratio: 0.57; 95% confidence interval: 0.37 to 0.89; p=0.013 |
os = overall survival.